Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. [electronic resource]
Producer: 20010426Description: 13-9 p. digitalISSN:- 0093-7754
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Breast Neoplasms -- drug therapy
- Cisplatin -- administration & dosage
- Clinical Trials as Topic
- Docetaxel
- Drug Synergism
- Genes, erbB-2
- Heart Failure -- chemically induced
- Humans
- Paclitaxel -- administration & dosage
- Prognosis
- Proto-Oncogene Mas
- Taxoids
- Trastuzumab
No physical items for this record
Publication Type: Journal Article; Review
There are no comments on this title.
Log in to your account to post a comment.